Department of Cardiology, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Nantong, 226000, China.
Department of Geriatrics, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Lung. 2024 Dec;202(6):831-843. doi: 10.1007/s00408-024-00754-7. Epub 2024 Oct 25.
This study explored the expression and diagnostic value of differentially expressed miR-3591-5p in congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH).
A total of 110 CHD patients were divided into four groups based on their mean pulmonary artery pressure (PAPm). The plasma miR-3591-5p expression was determined by reverse transcription polymerase chain reaction. The correlation between the miR-3591-5p expression and various clinical indices, as well as its diagnostic value for CHD-PAH patients, were analyzed.
The plasma levels of miR-3591-5p were significantly higher in the patients in the no PAH group, mild PAH group, and moderate to severe PAH group than in the control group, and they were significantly higher in the moderate to severe PAH group than in the no PAH group. Correlation analysis revealed that the miR-3591-5p expression level was significantly positively correlated with various clinical indicators, including the PAPm, pulmonary artery systolic pressure, brain natriuretic peptide, pulmonary vascular resistance, red blood cell distribution width, uric acid, Na + , systolic blood pressure, left atrial internal dimension, left ventricular end-diastolic dimension, and left ventricular end-systolic dimension. Univariate and multivariate regression analyses identified the plasma miR-3591-5p level as an independent risk factor for CHD-PAH. Receiver operating characteristic curve analysis demonstrated that the plasma miR-3591-5p level had a moderate diagnostic value for CHD-PAH, which was further improved when combined with a B-type natriuretic peptide.
This study identified the expression profiles of differentially expressed plasma miRNAs in patients with CHD-PAH, focusing on the upregulation of miR-3591-5p. Bioinformatics analysis suggested that miR-3591-5p is involved in the pathogenesis of CHD-PAH and may serve as a circulating biomarker that may have diagnostic and prognostic value in CHD-PAH.
本研究旨在探讨差异表达的 miR-3591-5p 在先天性心脏病相关肺动脉高压（CHD-PAH）中的表达及其诊断价值。
根据平均肺动脉压（PAPm），将 110 例 CHD 患者分为四组。采用逆转录聚合酶链反应检测血浆 miR-3591-5p 的表达。分析 miR-3591-5p 表达与各种临床指标的相关性及其对 CHD-PAH 患者的诊断价值。
无 PAH 组、轻度 PAH 组、中重度 PAH 组患者血浆 miR-3591-5p 水平明显高于对照组，且中重度 PAH 组明显高于无 PAH 组。相关性分析显示，miR-3591-5p 表达水平与 PAPm、肺动脉收缩压、脑利钠肽、肺血管阻力、红细胞分布宽度、尿酸、Na+、收缩压、左心房内径、左心室舒张末径、左心室收缩末径等各项临床指标均呈显著正相关。单因素和多因素回归分析均表明，血浆 miR-3591-5p 水平是 CHD-PAH 的独立危险因素。受试者工作特征曲线分析表明，血浆 miR-3591-5p 水平对 CHD-PAH 具有中等诊断价值，与 B 型利钠肽联合应用时可进一步提高诊断价值。
本研究鉴定了 CHD-PAH 患者差异表达血浆 miRNAs 的表达谱，重点关注 miR-3591-5p 的上调。生物信息学分析表明，miR-3591-5p 参与了 CHD-PAH 的发病机制，可能作为一种循环生物标志物，对 CHD-PAH 具有诊断和预后价值。
